Search | Clinical Trials Finder

Conditions: Type 1 Diabetes
Interventions: blood draw; Other
Lead sponsor: University of Florida; Other
Eligibility: 0 Years to 100 Years
Enrollment: 2,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2085
U.S. locations: 3
States / cities: Gainesville, Florida • Columbus, Ohio • Houston, Texas

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib; Procedure · Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Minutes and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 266
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 222 more

Conditions: Neonatal Anemia
Interventions: Transfused Biotin RBCs - Adults Phase I, Transfused Biotin RBCs - Infants Phase II, Transfused Biotin RBCs - Infants Phase III; Biological
Lead sponsor: John A Widness; Other
Eligibility: 1 Hour to 6 Months
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: Iowa City, Iowa

Conditions: Head and Neck Cancer
Interventions: Nivolumab, Ipilimumab, Standard of Care Surgery; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Blood collection, Tissue collection; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Ketosis
Interventions: Ketone Supplement, Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale, Blood Draw, Urine Analysis; Dietary Supplement · Behavioral · Biological + 1 more
Lead sponsor: Ohio State University; Other
Eligibility: 20 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Novato, California • Columbus, Ohio

Conditions: Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide, Fludarabine Phosphate, Total-Body Irradiation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, X-Ray Imaging; Procedure · Biological · Drug + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Hutchinson-Gilford Progeria Syndrome
Interventions: Progerinin, Lonafarnib; Drug
Lead sponsor: PRG Science & Technology Co., Ltd.; Industry
Eligibility: 1 Year and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
Interventions: CUDC-907; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 1 Year to 21 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more

Conditions: Cancer
Interventions: SOZO Device, DEXA Scan; Device
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Computed Tomography, Magnetic Resonance Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan; Drug · Biological · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Melanoma
Interventions: Blood draw (before surgery), Blood draw (every 3 months), Blood draw (at diagnosis); Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer
Interventions: Cisplatin, Carboplatin, Etoposide, Pembrolizumab, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Radiation Therapy; Drug · Biological · Procedure + 1 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Docetaxel, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 611
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 392 more

Conditions: Crohn's Disease
Interventions: Biopsies, stool and blood collection; Other
Lead sponsor: Enterome; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Functional Magnetic Resonance Imaging, Interview, Psilocybine, Psychotherapy, Questionnaire Administration; Procedure · Other · Drug + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy, Intrafraction Motion Monitoring, Magnetic Resonance Imaging, Questionnaire Administration; Procedure · Radiation · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myotonic Dystrophy
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 5 Years and older
Enrollment: 215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Healthy Volunteers
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2043
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma, COPD, Chronic Obstructive Pulmonary Disease
Interventions: Blood draw, Urine, Lung function measurements, Fractional Exhaled Nitric Oxide (FENO); Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 12,255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 40
States / cities: Loma Linda, California • Long Beach, California • Roseville, California + 33 more

Conditions: Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions: Vaginal Fluid Collection, Blood Collection; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 20 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Dual-Energy Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Sickle Cell Trait
Interventions: Biologic Specimen Collection; Other
Lead sponsor: National Alliance for Sickle Cell Centers; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Loma Linda, California • Wilmington, Delaware + 7 more

Search by objective public record fields.

Immune Function and the Progression to T1D

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Red Blood Cell (RBC) Survival Following Transfusion in Infants

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Memory Phenotype and PD-1 Inhibition Response in Oral Cancer

Variations in Ketone Metabolism

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women With Breast Cancer Receiving Chemotherapy

Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Body Composition Post Cancer Treatment

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients

Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids

Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial

Extracellular RNA Biomarkers of Myotonic Dystrophy

Sample Collection From Healthy Volunteers for Assay Optimization

Observational Study of Obstructive Lung Disease (NOVELTY)

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)